Servier announced acquisition of KER-0193, an oral small molecule modulator targeting Fragile X syndrome (FXS) from UK biotech Kaerus Bioscience for up to $450 million. The move bolsters Servier’s neurology franchise, focusing on rare conditions with high unmet need. KER-0193 demonstrated safety, good pharmacokinetics, and proof of mechanism in Phase I trials and is set for Phase II proof-of-concept studies in FXS patients. FXS is a leading inherited cause of autism spectrum disorder and intellectual disability with no approved treatments, making this deal a strategic addition to Servier’s pipeline.